Floatz logo

Bpx-501 T Cells

Leukemia, Acute Myeloid (AML), Child

Bellicum PharmaceuticalsCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the Leukemia, Acute Myeloid (AML), Child cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Joanna Yi
Phase 3BBB
Cytosin-Arabinosid
Children's Oncology Group
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Bpx-501 T Cells is also rated in:

inborn error of immunityDormant
CC
Indicative ·
47 / 100
View asset →
aplastic anemiaDormant
CC
Indicative ·
47 / 100
View asset →
osteopetrosisDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →